[{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi","highestDevelopmentStatusID":"10","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang ","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang ","highestDevelopmentStatusID":"10","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang "},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Peking University Third Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Peking University Third Hospital","highestDevelopmentStatusID":"1","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Peking University Third Hospital"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"Ottawa Fertility Centre","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Ottawa Fertility Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Fertility Centre \/ EMD Serono","highestDevelopmentStatusID":"8","companyTruncated":"Ottawa Fertility Centre \/ EMD Serono"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University Health Centre Research Institute \/ EMD Serono","highestDevelopmentStatusID":"8","companyTruncated":"McGill University Health Centre Research Institute \/ EMD Serono"},{"orgOrder":0,"company":"Rebecca Knickmeyer Santelli, PhD","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Rebecca Knickmeyer Santelli, PhD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rebecca Knickmeyer Santelli, PhD \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Rebecca Knickmeyer Santelli, PhD \/ Pfizer Inc"}]

Find Clinical Drug Pipeline Developments & Deals for Somatotropin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase IV

                          Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Achondroplasia.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          April 29, 2022

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase III

                          Sponsor : Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prader-Willi Syndrome.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          June 12, 2018

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase III

                          Sponsor : Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dwarfism.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          May 24, 2018

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase III

                          Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          August 10, 2017

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          McGill University Health Centre Research Institute

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          McGill University Health Centre Research Institute

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Somatotropin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          March 27, 2017

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : EMD Serono

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Polycystic Ovary Syndrome.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          June 16, 2016

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Peking University Third Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Genotropin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 22, 2013

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dwarfism, Pituitary.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          May 24, 2012

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Rebecca Knickmeyer Santelli, PhD

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Rebecca Knickmeyer Santelli, PhD

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Somatotropin is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Turner Syndrome.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          June 07, 2011

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Ottawa Fertility Centre

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ottawa Fertility Centre

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Somatotropin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Infertility.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 17, 2010

                          Lead Product(s) : Recombinant Human Growth Hormone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : EMD Serono

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank